# GLP-1 Drugs Like Ozempic, Wegovy May Help With Binge Eating Disorder
Medications designed for weight loss and diabetes management show promise in treating binge eating disorder, according to emerging research. GLP-1 receptor agonists, including semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro), appear to reduce binge eating episodes by affecting how the brain regulates appetite and satiety.
Binge eating disorder affects roughly 2.8 million adults in the United States. Unlike other eating disorders, it involves consuming large quantities of food in short periods while feeling out of control, often followed by shame or distress. Current treatment relies primarily on therapy and behavioral interventions, with limited medication options.
GLP-1 drugs work by mimicking glucagon-like peptide-1, a hormone that signals fullness to the brain. This mechanism not only promotes weight loss but also appears to reduce the psychological drive to overeat. Early studies suggest these medications decrease both the frequency and severity of binge episodes in people taking them for weight management.
Researchers emphasize that while these results look encouraging, GLP-1 drugs were not designed specifically for binge eating disorder treatment. Insurance companies may not yet cover them for this indication, and more rigorous clinical trials are needed to establish efficacy and safety for this population.
The potential benefits come with considerations. GLP-1 medications can cause gastrointestinal side effects like nausea, vomiting, and constipation. They also carry rare but serious risks, including pancreatitis and gallbladder issues. Cost remains a barrier, with monthly prescriptions running $900 to $1,500 without insurance.
Parents or caregivers noticing signs of binge